Fibroblast growth factor-23 and cardiovascular events in CKD.

PubWeight™: 1.78‹?› | Rank: Top 3%

🔗 View Article (PMC 3904568)

Published in J Am Soc Nephrol on October 24, 2013

Authors

Julia J Scialla1, Huiliang Xie, Mahboob Rahman, Amanda Hyre Anderson, Tamara Isakova, Akinlolu Ojo, Xiaoming Zhang, Lisa Nessel, Takayuki Hamano, Juan E Grunwald, Dominic S Raj, Wei Yang, Jiang He, James P Lash, Alan S Go, John W Kusek, Harold Feldman, Myles Wolf, Chronic Renal Insufficiency Cohort (CRIC) Study Investigators

Author Affiliations

1: University of Miami Miller School of Medicine, Miami, Florida;

Associated clinical trials:

New Biomarkers in Heart- and Renal Failure (IM19 Register) | NCT02830464

Articles citing this

Fibroblast growth factor 23 and risk of incident stroke in community-living adults. Stroke (2015) 2.06

Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus. Am J Nephrol (2015) 1.42

Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation. Kidney Int (2016) 1.39

Identification of incident CKD stage 3 in research studies. Am J Kidney Dis (2014) 1.29

Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc (2014) 1.07

Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr Opin Nephrol Hypertens (2014) 1.03

Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD. J Am Soc Nephrol (2015) 0.92

High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort. Pediatr Nephrol (2014) 0.92

Mineral (Mal)Adaptation to Kidney Disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol (2015) 0.91

Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blockade in an animal model of CKD. Nephrol Dial Transplant (2014) 0.91

Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis (2015) 0.87

Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. J Am Heart Assoc (2015) 0.86

The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol (2014) 0.86

Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol (2014) 0.84

Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int (2016) 0.83

Chronic Renal Insufficiency Cohort Study (CRIC): Overview and Summary of Selected Findings. Clin J Am Soc Nephrol (2015) 0.82

Fibroblast growth factor 23 and 25-hydroxyvitamin D levels are associated with estimated glomerular filtration rate decline. Kidney Int Suppl (2011) (2013) 0.82

Abnormalities in biomarkers of mineral and bone metabolism in kidney donors. Kidney Int (2016) 0.82

Fibroblast growth factor 23 in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the Intraaortic Balloon Pump in Cardiogenic Shock II (IABP-SHOCK II) trial. Crit Care (2014) 0.82

Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep (2014) 0.81

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children. Clin J Am Soc Nephrol (2016) 0.80

Mineral metabolism and cardiovascular disease in CKD. Clin Exp Nephrol (2017) 0.79

Vitamin D and anemia: insights into an emerging association. Curr Opin Endocrinol Diabetes Obes (2015) 0.79

Fibroblast growth factor 23 and sudden versus non-sudden cardiac death: the Cardiovascular Health Study. Am J Kidney Dis (2015) 0.79

Fibroblast growth factor 23 and incident CKD in type 2 diabetes. Clin J Am Soc Nephrol (2014) 0.79

Phosphate and FGF-23 homeostasis after kidney transplantation. Nat Rev Nephrol (2015) 0.79

Clinical features of CKD-MBD in Japan: cohort studies and registry. Clin Exp Nephrol (2016) 0.78

Chronic Hyperphosphatemia and Vascular Calcification Are Reduced by Stable Delivery of Soluble Klotho. J Am Soc Nephrol (2016) 0.78

The Kidney-Vascular-Bone Axis in the Chronic Kidney Disease-Mineral Bone Disorder. Transplantation (2016) 0.78

Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure. Biomed Res Int (2015) 0.78

Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients. BMC Nephrol (2014) 0.78

Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability. Dis Markers (2015) 0.77

Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy. Medicine (Baltimore) (2016) 0.77

Hunt for the culprit of cardiovascular injury in kidney disease. Cardiovasc Res (2015) 0.77

Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol (2016) 0.77

Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease? World J Cardiol (2014) 0.76

Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease. Dis Markers (2016) 0.76

Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study. JAMA Cardiol (2016) 0.76

Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study. Nephrol Dial Transplant (2015) 0.76

Longitudinal assessment of cardiac morphology and function following kidney transplantation. Clin Transplant (2016) 0.75

The Urinary Phosphate to Serum Fibroblast Growth Factor 23 Ratio Is a Useful Marker of Atherosclerosis in Early-Stage Chronic Kidney Disease. PLoS One (2016) 0.75

The systemic nature of CKD. Nat Rev Nephrol (2017) 0.75

Energy-dense diets increase FGF23, lead to phosphorus retention and promote vascular calcifications in rats. Sci Rep (2016) 0.75

Correlates and Longitudinal Renal and Cardiovascular Implications of FGF23 Levels in HIV-Positive Individuals. PLoS One (2016) 0.75

The biomarker niche for fibroblast growth factor 23 testing in CKD. J Am Soc Nephrol (2014) 0.75

Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia. J Am Soc Nephrol (2017) 0.75

Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT). Nephron (2016) 0.75

Epidemiologic insights on the role of fibroblast growth factor 23 in cardiovascular disease. Curr Opin Nephrol Hypertens (2015) 0.75

High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4. Medicine (Baltimore) (2016) 0.75

Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. Front Cardiovasc Med (2017) 0.75

The effect of nephrectomy on Klotho, FGF-23 and bone metabolism. Int Urol Nephrol (2017) 0.75

Association between Serum Soluble Klotho Levels and Mortality in Chronic Hemodialysis Patients. Int J Endocrinol (2015) 0.75

Fibroblast growth factor 23 and heart failure: the plot thickens. Nephrol Dial Transplant (2015) 0.75

Not only for the risk of bone fracture. J Bone Miner Metab (2015) 0.75

Associations of Conventional Echocardiographic Measures with Incident Heart Failure and Mortality: The Chronic Renal Insufficiency Cohort. Clin J Am Soc Nephrol (2016) 0.75

Non-Linear Heart Rate Variability Indices in the Frequent Hemodialysis Network Trials of Chronic Hemodialysis Patients. Blood Purif (2015) 0.75

Is Fibroblast growth factor 23 the leading cause of increased mortality among chronic kidney disease patients? A narrative review. J Adv Res (2017) 0.75

Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int (2016) 0.75

Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. J Am Heart Assoc (2017) 0.75

Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open (2017) 0.75

The role of epigenetics in renal ageing. Nat Rev Nephrol (2017) 0.75

Blood Pressure and Risk of Cardiovascular Events in Patients on Chronic Hemodialysis: The CRIC Study (Chronic Renal Insufficiency Cohort). Hypertension (2017) 0.75

The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study. Pediatr Nephrol (2017) 0.75

Cardiovascular alterations do exist in children with stage-2 chronic kidney disease. Clin Exp Nephrol (2016) 0.75

Fibroblast growth factor-23 is independently associated with cardiac mass in African-American adolescent males. J Am Soc Hypertens (2017) 0.75

Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond? Pediatr Nephrol (2014) 0.75

Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism. Calcif Tissue Int (2017) 0.75

Chronic Kidney Disease-Mineral and Bone Disorder in Asia. Kidney Dis (Basel) (2017) 0.75

Phosphate Additive Avoidance in Chronic Kidney Disease. Diabetes Spectr (2017) 0.75

Articles cited by this

A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med (2004) 49.19

Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet (2010) 18.36

Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med (2006) 17.55

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79

FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA (2010) 6.11

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86

The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87

Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74

Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol (2010) 4.59

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet (2012) 4.25

Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16

FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52

Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation (2006) 3.31

Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation (2012) 3.07

Prevalence and determinants of troponin T elevation in the general population. Circulation (2006) 2.84

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70

Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (2012) 2.61

Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol (2007) 2.53

Cardiac troponin and outcome in acute heart failure. N Engl J Med (2008) 2.41

Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol (2009) 2.29

Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol (2012) 2.22

Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82

FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 1.78

Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis (2006) 1.68

Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int (2013) 1.66

Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone (2012) 1.62

Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol (2008) 1.60

Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol (2001) 1.58

The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J (2011) 1.51

Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J (2011) 1.49

Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol (2012) 1.48

Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol (2012) 1.41

Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol (2011) 1.36

Chronic kidney disease and the risk of heart failure in men. Circ Heart Fail (2011) 1.05

Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure. Eur J Clin Invest (2011) 1.02

The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens (2004) 0.94

Fibroblast growth factor 23 and left ventricular hypertrophy in children on dialysis. Pediatr Nephrol (2012) 0.89

Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD. Am J Kidney Dis (2012) 0.87

Articles by these authors

A new equation to estimate glomerular filtration rate. Ann Intern Med (2009) 71.41

Prevalence of chronic kidney disease in the United States. JAMA (2007) 38.98

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med (2006) 32.81

Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76

Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2011) 31.98

Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2012) 30.79

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2013) 28.02

Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation (2014) 22.74

Prevalence of diabetes among men and women in China. N Engl J Med (2010) 19.98

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14

Linking long-term dietary patterns with gut microbial enterotypes. Science (2011) 17.30

Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med (2012) 14.99

Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem (2007) 13.80

Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology (2012) 11.91

Prevalence and control of diabetes in Chinese adults. JAMA (2013) 11.73

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25

Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52

Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation (2015) 10.14

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19

Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med (2005) 8.95

Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89

Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med (2010) 8.48

Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med (2010) 8.28

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA (2002) 7.93

Burch colposuspension versus fascial sling to reduce urinary stress incontinence. N Engl J Med (2007) 7.90

H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine gamma-lyase. Science (2008) 7.89

The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and Methods. J Am Soc Nephrol (2003) 7.79

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Body mass index and risk for end-stage renal disease. Ann Intern Med (2006) 7.56

Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA (2008) 7.50

FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22

Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med (2003) 6.70

Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation (2014) 6.55

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med (2003) 6.41

Worldwide prevalence of hypertension: a systematic review. J Hypertens (2004) 6.25

Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation (2012) 6.24

Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation (2013) 6.13

Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol (2007) 6.00

Effect of aerobic exercise on blood pressure: a meta-analysis of randomized, controlled trials. Ann Intern Med (2002) 5.92

Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int (2008) 5.90

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86

Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol (2005) 5.76

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care (2011) 5.63

Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med (2009) 5.58

The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med (2004) 5.45

The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med (2005) 5.45

Crystal structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell (2005) 5.43

Effects of low-carbohydrate and low-fat diets: a randomized trial. Ann Intern Med (2014) 5.31

Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int (2009) 5.28

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2007) 5.26

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06

Prevalence of the metabolic syndrome and overweight among adults in China. Lancet (2005) 5.05

APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med (2013) 5.00

Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. BMC Microbiol (2010) 4.97

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87

Mortality attributable to smoking in China. N Engl J Med (2009) 4.75

Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int (2011) 4.74

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71

Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med (2006) 4.69

A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63

A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med (2012) 4.59

Fast, three-dimensional super-resolution imaging of live cells. Nat Methods (2011) 4.52

Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol (2005) 4.44

RAG2 PHD finger couples histone H3 lysine 4 trimethylation with V(D)J recombination. Nature (2007) 4.35

Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis (2002) 4.34

Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med (2009) 4.19